NASDAQ: GPCRStructure Therapeutics Inc Stock
$37.07-0.75 (-1.98%)
Updated Apr 17, 2024
GPCR Price
$37.07
Fair Value Price
$3.38
Market Cap
$1.73B
52 Week Low
$21.79
52 Week High
$75.02
P/E
-15.26x
P/B
3.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$89.62M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$79M
Beta
0.92
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GPCR Overview
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GPCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GPCR ($37.07) is overvalued by 995.13% relative to our estimate of its Fair Value price of $3.38 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GPCR ($37.07) is not significantly undervalued (995.13%) relative to our estimate of its Fair Value price of $3.38 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GPCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GPCR due diligence checks available for Premium users.
Be the first to know about important GPCR news, forecast changes, insider trades & much more!
GPCR News
Valuation
GPCR fair value
Fair Value of GPCR stock based on Discounted Cash Flow (DCF)
Price
$37.07
Fair Value
$3.38
Overvalued by
995.13%
GPCR ($37.07) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GPCR ($37.07) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GPCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GPCR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-15.26x
Industry
15.83x
Market
41.64x
GPCR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.81x
Industry
5.83x
GPCR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GPCR's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.5M
Profit Margin
0%
GPCR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$482.0M
Liabilities
$29.1M
Debt to equity
0.06
GPCR's short-term assets ($473.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GPCR's short-term assets ($473.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GPCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.7M
Investing
-$180.7M
Financing
$281.6M
GPCR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GPCR vs Biotech Stocks
Structure Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.